Zealand Pharma to pay $350M to Roche
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Zealand engineered petrelintide in a way that enables it ... develop petrelintide as a future foundational therapy,” Roche Pharmaceuticals CEO Teresa Graham said in a prepared statement.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results